Skip to main content
. 2023 Sep 8;78(11):2645–2652. doi: 10.1093/jac/dkad269

Figure 1.

Figure 1.

Study design. AML, acute myeloid leukaemia; CT, remission induction chemotherapy; D, day; EOT, end of treatment; FMGX, fosmanogepix; FU, follow-up; IV, intravenous; MGX, manogepix; PK, pharmacokinetics; PO, oral; POS, posaconazole; QD, once a day. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.